{
    "2021-10-20": [
        [
            {
                "time": "2021-06-30",
                "original_text": "健帆生物：公司现金理财产品已全部赎回",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "现金理财",
                        "赎回"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-30",
                "original_text": "健帆生物：公司委托理财产品列报至“交易性金融资产”科目",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "委托理财",
                        "交易性金融资产"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-30",
                "original_text": "健帆生物：限售股主要是高管锁定股及股权激励限售股",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "限售股",
                        "高管锁定股",
                        "股权激励"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-06-30",
                "original_text": "健帆生物：上半年营业成本增加主要系本期产品销量增加所致",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "营业成本",
                        "产品销量",
                        "增加"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-30",
                "original_text": "健帆生物：公司不存在控股股东资金占用、非经营性资金占用及其他关联资金往来的情况",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "控股股东",
                        "资金占用",
                        "非经营性资金"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-30",
                "original_text": "健帆生物：公司2021年上半年的营业成本为1.75亿元，相比去年同期增加0.5亿元，主要系本期产品销量增加所致",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "营业成本",
                        "产品销量",
                        "增加",
                        "同比"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}